Genprex, Inc. (GNPX)
Genprex, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Austin, TX, US. The stock last traded at $4.68, up 4.70% on the session, giving a market capitalisation of $2.4M. On trailing twelve-month figures it carries a trailing P/E of -0.01, a net margin of 0.0%. Its beta of -0.89 implies it has historically moved less than the broad market.
Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.
Genprex, Inc. is most often compared with the following Healthcare names: